Philip L Lorenzi
Overview
Explore the profile of Philip L Lorenzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
5862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahmud I, Chan W, Yannell K, Simmermaker C, Van de Bittner G, Wu L, et al.
bioRxiv
. 2025 Mar;
PMID: 40027784
Poor therapeutic index is a principal cause of drug attrition during development. A case in point is L-asparaginase (ASNase), an enzyme-drug approved for treatment of pediatric acute lymphoblastic leukemia (ALL)...
2.
Bowen M, Melendez B, Zhang Q, Moreno D, Peralta L, Chan W, et al.
JCI Insight
. 2025 Feb;
PMID: 39964762
Lynch syndrome (LS), caused by inherited mutations in DNA mismatch repair genes including MSH2, carries a 60% lifetime risk of developing endometrial cancer (EC). Beyond hypermutability, mechanisms driving LS-associated EC...
3.
Qin L, Moreno Rueda L, Ray U, Mahmud I, Tan L, Lorenzi P, et al.
Blood
. 2025 Feb;
PMID: 39912779
Plasma cell dyscrasias encompass a spectrum from the precursors monoclonal gammopathy of undetermined significance and smoldering myeloma to symptomatic myeloma, but the genes that enable progression and confer poor prognosis...
4.
Mahmud I, Wei B, Veillon L, Tan L, Martinez S, Tran B, et al.
Nat Commun
. 2025 Feb;
16(1):1347.
PMID: 39905052
Ion suppression is a major problem in mass spectrometry (MS)-based metabolomics; it can dramatically decrease measurement accuracy, precision, and sensitivity. Here we report a method, the IROA TruQuant Workflow, that...
5.
Freitas-Cortez M, Masrorpour F, Jiang H, Mahmud I, Lu Y, Huang A, et al.
Mol Cancer
. 2025 Feb;
24(1):40.
PMID: 39901247
Background: Cancer creates an immunosuppressive environment that hampers immune responses, allowing tumors to grow and resist therapy. One way the immune system fights back is by inducing ferroptosis, a type...
6.
Yang B, Savarraj J, Chen H, Hinds S, Torres G, Ryan A, et al.
medRxiv
. 2025 Jan;
PMID: 39830284
Background: Aneurysmal subarachnoid hemorrhage (aSAH) causes systemic changes that contribute to delayed cerebral ischemia (DCI) and morbidity. Circulating metabolites reflecting underlying pathophysiological mechanisms warrant investigation as biomarker candidates. Methods: Blood...
7.
Casso-Chapa B, Vazquez Gonzalez N, Le N, Palaskas N, Nead K, Eutsey L, et al.
Arterioscler Thromb Vasc Biol
. 2025 Jan;
45(3):372-385.
PMID: 39817327
Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease,...
8.
Yang B, Blackburn S, Lorenzi P, Choi H, Gusdon A
Neurotherapeutics
. 2024 Dec;
22(1):e00504.
PMID: 39701893
Aneurysmal subarachnoid hemorrhage (aSAH) results in a complex systemic response that is critical to the pathophysiology of late complications and has important effects on outcomes. Omics techniques have expanded our...
9.
WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer
Citron F, Ho I, Balestrieri C, Liu Z, Yen E, Cecchetto L, et al.
bioRxiv
. 2024 Nov;
PMID: 39484624
It is unclear how cells counteract the potentially harmful effects of uncoordinated DNA replication in the context of oncogenic stress. Here, we identify the WRAD (WDR5/RBBP5/ASH2L/DPY30) core as a modulator...
10.
Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, et al.
Br J Cancer
. 2024 Oct;
131(11):1846-1857.
PMID: 39394450
Background: Uveal melanoma (UM) is a highly aggressive disease with very few treatment options. We previously demonstrated that mUM is characterized by high oxidative phosphorylation (OXPHOS). Here we tested the...